Novartis News
11 articles
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
Roche has announced its acquisition of 89bio, a clinical-stage biopharmaceutical company, for $3.5 billion. This strategic move aims to enhance Roches portfolio in cardiovascular, renal, and metabolic diseases by adding 89bios promising phase III candidate, pegozafermin, to its pipeline. Pegozafermin is in late-stage development for treating metabolic dysfunction-associated steatohepatitis (MASH) in fibrotic and cirrhotic patients. The acquisition, approved by both companies boards, is expected to close in the fourth quarter of 2025. The deal includes a contingent value right (CVR) for 89bio stockholders, potentially increasing the total consideration by up to $1 billion if certain sales milestones are met. This acquisition is seen as a positive growth opportunity for Roche, aligning with its strategic focus on lucrative therapeutic areas.
Acquisition
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
The article discusses the addition of the Multiple Sclerosis - Global Clinical Trials Review, 2025 report to ResearchAndMarkets.coms offerings. This report provides a comprehensive overview of the global landscape of clinical trials for Multiple Sclerosis, including data by region, phase, and sponsor. It highlights top drugs and trial trends, aiding in strategic decision-making and competitive advantage. The report is generated using a proprietary database and includes data from over 80 clinical trial registries and other sources. It aims to assist in formulating business strategies, identifying key locations for trials, and understanding global market opportunities.
Product Stage
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
The article discusses the positive performance of U.S. stock indices on July 17, 2025, driven by growth factors such as improved retail sales and decreased unemployment claims. Notably, Netflixs better-than-expected earnings results contributed to investor confidence and Wall Streets performance. The article advises investors to consider low-leverage stocks like Novartis, ResMed Inc., Wabtec, Elbit Systems, and Ingredion Inc. to mitigate risks associated with market volatility. It explains the concept of leverage and its implications for financial risk, emphasizing the importance of selecting companies with lower debt-to-equity ratios for safer investments.
Biotech Alert: Searches spiking for these stocks today
Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases. Their lead product, nebokitug, is a monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation. Nebokitug has shown promise in clinical trials, demonstrating a favorable safety profile and potential to treat severe fibro-inflammatory diseases. The company is preparing for a Phase 3 trial for primary sclerosing cholangitis (PSC), following positive Phase 2 results. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. This article highlights the growth potential of Chemomab Therapeutics, as well as other biotech companies experiencing increased interest.
Product StageFDA approved/pending approval
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
Pharma multinational Novartis International AG has made a $10 million equity investment in Ayala Pharmaceuticals Inc., a clinical-stage company developing targeted therapies for genetically-defined cancers. The investment is part of a licensing option agreement signed between the two companies. Novartis will evaluate one of Ayalas drug candidates for the treatment of multiple myeloma. Ayala will retain licensing rights for all other indications of the drug.
Investment
Ayala signs licensing deal with Novartis for blood cancer drug
Ayala Pharmaceuticals has entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma. Ayala will receive a $10 million equity investment from Novartis and is eligible for milestone payments. Novartis will conduct studies to evaluate AL102 in combination with its B-cell maturation antigen (BCMA) therapies. Ayala raised $17 million in a Series A financing round earlier this year. AL102 is an oral small-molecule that inhibits gamma secretase and is being investigated as a potential treatment for multiple myeloma.
InvestmentPartners
Novartis to invest in $60m Gamida Cell Nasdaq IPO
Gamida Cell, an Israeli stem cell cancer therapy developer, has filed a revised public registration statement with the US Securities and Exchange Commission (SEC) to raise $50-60 million on Nasdaq at a company valuation of $275 million. The companys shareholders, including Novartis, will invest $30 million in the offering. Gamida Cell is currently enrolling patients in a Phase III clinical trial for its most advanced product candidate, NiCord, which is a NAM-expanded cord blood cell therapy. The company has raised over $100 million to date, including $40 million in June 2017.
Public TradingInvestment
Novartis seeks new Israeli technologies
Novartis AG has increased its interest in Israel by investing $35 million in Gamida Cell and signing a deal with BiolineRX Ltd. Novartis recognizes the technology in Israel and believes that BioLineRx is suitable for developing these technologies. The person directing Novartiss general strategy is David Epstein, who has served as Novartis Pharmaceuticals Division Head since 2010. Epsteins appointment indicates the companys growing focus on cancer treatment. Novartis has also announced a partnership with Google for digital healthcare. The company is looking to strengthen its ties with young start-ups and make targeted acquisitions, primarily through BioLineRx. Novartis is focused on developing cell therapy and gene therapy technologies and has a promising product pipeline.
InvestmentPartners
Optonol: Reaping $180m from a device the size of a grain of rice
Optonol, a company that develops microscopic drainage shunts for the treatment of glaucoma, will be sold to Alcon in a deal worth $200 million. Optonols shareholders will receive additional payments based on sales milestones. The sale is expected to benefit Pitango venture capital fund the most, estimated to receive $60 million. Israel HealthCare Ventures also owns a 13% stake in the company. Optonols product line, including the Ex-PRESS, helps reduce intraocular pressure in glaucoma patients. The company was founded in 1996 as a spin-off of Medinol and currently has 20 to 30 employees. Alcon, a U.S.-based medical giant, manufactures devices for ocular surgery and eye treatment products.
Acquisition